An aggressive systemic mastocytosis preceded by ovarian dysgerminoma

被引:9
作者
Tsutsumi, Makiko [1 ]
Miura, Hiroki [2 ]
Inagaki, Hidehito [1 ]
Shinkai, Yasuko [1 ]
Kato, Asuka [1 ,3 ]
Kato, Takema [1 ]
Hamada-Tsutsumi, Susumu [4 ]
Tanaka, Makito [2 ]
Kudo, Kazuko [2 ]
Yoshikawa, Tetsushi [2 ]
Kurahashi, Hiroki [1 ]
机构
[1] Fujita Hlth Univ, Inst Comprehens Med Sci, Div Mol Genet, 1-98 Dengakugakubo, Toyoake, Aichi 4701192, Japan
[2] Fujita Hlth Univ, Dept Pediat, Sch Med, Toyoake, Aichi, Japan
[3] Nagoya Univ, Grad Sch Med, ITOCHU Collaborat Res Mol Targeted Canc Treatment, Nagoya, Aichi, Japan
[4] Nagoya City Univ, Dept Virol & Liver Unit, Grad Sch Med Sci, Nagoya, Aichi, Japan
关键词
Aggressive systemic mastocytosis; KIT; Dysgerminoma; Germ cell tumor; TP53; Loss of heterozygosity; ACUTE MYELOID-LEUKEMIA; GERM-CELL TUMOR; MAST-CELLS; MUTATION; CLASSIFICATION;
D O I
10.1186/s12885-020-07653-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundAggressive systemic mastocytosis (ASM) is a rare malignant disease characterized by disordered mast cell accumulation in various organs. We here describe a female ASM patient with a previous history of ovarian dysgerminoma.MethodsMolecular cytogenomic analyses were performed to elucidate an etiological link between the ASM and dysgerminoma of the patient.ResultsThis patient was affected by ovarian dysgerminoma which was treated by chemotherapy and surgical resection. Having subsequently been in complete remission for 2years, she developed symptoms of ASM. A somatic D816A mutation in the KIT gene was detected in her bone marrow, which facilitated the diagnosis of ASM. Unexpectedly, this KIT D816A variant was also detected in the prior ovarian dysgerminoma sample. Whole-exome sequencing allowed us to identify a somatic nonsense mutation of the TP53 gene in the bone marrow, but not in the dysgerminoma. Microarray analysis of the patient's bone marrow revealed a copy-number-neutral loss of heterozygosity at the TP53 locus, suggestive of the homozygous nonsense mutation in the TP53 gene. In addition, the loss of heterozygosity at the TP53 locus was also detected in the dysgerminoma.ConclusionsThese results indicated that either the mast cells causing the ASM in this case had originated from the preceding ovarian dysgerminoma as a clonal evolution of a residual tumor cell, which acquired the TP53 mutation, or that both tumors developed from a common cancer stem cell carrying the KIT D816A variation.
引用
收藏
页数:7
相关论文
共 31 条
  • [1] KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis
    Arock, M.
    Sotlar, K.
    Akin, C.
    Broesby-Olsen, S.
    Hoermann, G.
    Escribano, L.
    Kristensen, T. K.
    Kluin-Nelemans, H. C.
    Hermine, O.
    Dubreuil, P.
    Sperr, W. R.
    Hartmann, K.
    Gotlib, J.
    Cross, N. C. P.
    Haferlach, T.
    Garcia-Montero, A.
    Orfao, A.
    Schwaab, J.
    Triggiani, M.
    Horny, H-P
    Metcalfe, D. D.
    Reiter, A.
    Valent, P.
    [J]. LEUKEMIA, 2015, 29 (06) : 1223 - 1232
  • [2] A PDE3A mutation in familial hypertension and brachydactyly syndrome
    Boda, Hiroko
    Uchida, Hidetoshi
    Takaiso, Nobue
    Ouchi, Yuya
    Fujita, Naoko
    Kuno, Asami
    Hata, Tadayoshi
    Nagatani, Arisa
    Funamoto, Yuri
    Miyata, Masafumi
    Yoshikawa, Tetsushi
    Kurahashi, Hiroki
    Inagaki, Hidehito
    [J]. JOURNAL OF HUMAN GENETICS, 2016, 61 (08) : 701 - 703
  • [3] SYSTEMIC MASTOCYTOSIS FOLLOWING MEDIASTINAL GERM-CELL TUMOR - AN ASSOCIATION CONFIRMED
    CHARIOT, P
    MONNET, I
    GAULARD, P
    ABDALSAMAD, I
    RUFFIE, P
    DECREMOUX, H
    [J]. HUMAN PATHOLOGY, 1993, 24 (01) : 111 - 112
  • [4] SYSTEMIC MAST-CELL DISEASE ASSOCIATED WITH PRIMARY MEDIASTINAL GERM-CELL TUMOR
    CHARIOT, P
    MONNET, I
    LELONG, F
    CHLEQ, C
    DROZ, JP
    DECREMOUX, H
    [J]. AMERICAN JOURNAL OF MEDICINE, 1991, 90 (03) : 381 - 385
  • [5] KIT Gene Mutation and Amplification in Dysgerminoma of the Ovary
    Cheng, Liang
    Roth, Lawrence M.
    Zhang, Shaobo
    Wang, Mingsheng
    Morton, Michael J.
    Zheng, Wenxin
    Karim, Fadi W. Abdul
    Montironi, Rodolfo
    Lopez-Beltran, Antonio
    [J]. CANCER, 2011, 117 (10) : 2096 - 2103
  • [6] TP53 and therapy-related myeloid neoplasms
    Chung, Jae
    Sallman, David A.
    Padron, Eric
    [J]. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2019, 32 (01) : 98 - 103
  • [7] Epidemiology of systemic mastocytosis in Denmark
    Cohen, Sarah S.
    Skovbo, Stine
    Vestergaard, Hanne
    Kristensen, Thomas
    Moller, Michael
    Bindslev-Jensen, Carsten
    Fryzek, Jon P.
    Broesby-Olsen, Sigurd
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2014, 166 (04) : 521 - 528
  • [8] Involvement of a common progenitor cell in core binding factor acute myeloid leukaemia associated with mastocytosis
    Cornet, Edouard
    Dumezy, Florent
    Roumier, Christophe
    Lepelley, Pascale
    Jouy, Nathalie
    Philippe, Nathalie
    Renneville, Aline
    Berthon, Celine
    Nelken, Brigitte
    Quesnel, Bruno
    Preudhomme, Claude
    [J]. LEUKEMIA RESEARCH, 2012, 36 (11) : 1330 - 1333
  • [9] Loss of Function of TET2 Cooperates with Constitutively Active KIT in Murine and Human Models of Mastocytosis
    De Vita, Serena
    Schneider, Rebekka K.
    Garcia, Michael
    Wood, Jenna
    Gavillet, Mathilde
    Ebert, Benjamin L.
    Gerbaulet, Alexander
    Roers, Axel
    Levine, Ross L.
    Mullally, Ann
    Williams, David A.
    [J]. PLOS ONE, 2014, 9 (05):
  • [10] Systemic mastocytosis following a malignant ovarian germ cell tumour
    Delacretaz, F
    Stalder, M
    MeugeMoraw, C
    Schmidt, PM
    Joris, F
    Kurt, AM
    DeWerra, P
    [J]. HISTOPATHOLOGY, 1997, 30 (06) : 582 - 584